Illumina's Q1 Earnings: Can They Keep the Sector's Momentum?

Illumina, a genomics powerhouse, is set to report its first-quarter earnings this Thursday, with analysts predicting a 2.9% year-over-year revenue increase, a stark contrast to last years 1.4% drop. The companys stock currently stands at $127.48, with an average price target of $136.67. Last quarter, Illumina exceeded expectations with a 5% revenue growth, and their full-year guidance surpassed Wall Streets predictions. The life sciences tools sector is thriving, with peers like West Pharmaceutical Services and Thermo Fisher posting strong growth and share increases. Illuminas stock has gained 5.5% in the past month, riding the sectors positive momentum. The upcoming earnings report could set the tone for the sectors future performance. Support the show:Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/1e3a875a5b7308ae